Evolving Approaches to CKD-MBD Address Cardiovascular and Fracture Risk

Why It Matters

These emerging therapies could shift the standard of care for CKD‑MBD, potentially lowering the leading causes of death—cardiovascular events and bone fractures—in a vulnerable patient population.

Key Takeaways

• FGF23 can rise 1000‑fold in ESKD, linking to cardiovascular death
• Tenapanor, a non‑absorbed phosphate inhibitor, reduces intestinal phosphate uptake
• Cinacalcet improves calcium‑sensing, lowering cardiovascular mortality in dialysis
• SNF472 blocks hydroxyapatite crystal growth, targeting vascular calcification
• α‑Klotho up‑regulation remains experimental, with no approved human therapy

Pulse Analysis

Patients with CKD and ESKD face a disproportionate burden of cardiovascular disease and bone fractures, driven by mineral and bone disorder (MBD). Traditional management has centered on normalizing serum phosphate, calcium, and parathyroid hormone levels, yet large observational studies show these measures alone have failed to curb excess mortality. The review underscores that the pathophysiology of MBD extends beyond simple phosphate overload, involving hormonal regulators and vascular calcification pathways that demand more nuanced interventions.

Emerging targets such as fibroblast growth factor‑23 (FGF23) and its co‑factor α‑Klotho are gaining attention. FGF23 spikes early in CKD and can increase up to a thousand‑fold in ESKD, correlating with higher cardiovascular risk. While direct FGF23 antagonists remain investigational, therapies that modulate its activity—like the calcimimetic cinacalcet—have demonstrated reductions in cardiovascular events. Newer agents, including the non‑systemic phosphate‑absorption inhibitor tenapanor and the hydroxyapatite crystal blocker SNF472, aim to limit intestinal phosphate uptake and vascular calcification respectively, offering mechanistic advantages over older resin‑based binders.

The clinical implications are significant. If forthcoming randomized trials confirm mortality or hospitalization benefits, nephrologists may adopt a multi‑targeted regimen that combines iron‑based binders, tenapanor, and calcimimetics to address both vascular and skeletal complications. However, challenges remain: adherence to multiple daily binders, gastrointestinal side effects, and the lack of approved α‑Klotho‑enhancing drugs. Robust evidence will be essential to justify broader insurance coverage and to integrate these therapies into guideline recommendations, ultimately aiming to reduce the high death rates that have plagued CKD‑MBD patients for decades.